Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

35.300
+1.7805.31%
Volume:13.13M
Turnover:457.36M
Market Cap:214.06B
PE:32.48
High:35.420
Open:33.200
Low:33.200
Close:33.520
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:2.05
T/O Rate:0.22%
Dividend:0.49
Dividend Rate:1.40%
EPS(LYR):1.087
ROE:19.40%
ROA:9.08%
PB:4.85
PE(LYR):32.48
PS:11.52

Loading ...

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Hansoh Pharmaceutical Group Stock Rises 5.3% in Hong Kong

Dow Jones
·
Sep 30

Movement Alert|HANSOH PHARMA Rises 3.16% in Regular Trading, Competitor B7-H3 ADC Withdrawal Boosts Outlook Amid Sector Rally

Market Focus
·
Sep 30

EU Withdrawal of Aumseqa Exposes Hansoh Pharma's Compliance Gaps and Global Ambitions

Deep News
·
Sep 29

JPMorgan: Merck/Daiichi Sankyo Withdrawal of B7-H3 ADC Filing Is a Positive for Hansoh Pharma/GSK's Ris-Rez

Stock News
·
Sep 28

Hansoh Pharma to Challenge EU Marketing Revocation for Aumolertinib

MT Newswires Live
·
Sep 28

Hansoh Pharma EU Marketing Authorization for Aumseqa Withdrawn, Company Plans to Resubmit Application

Stock News
·
Sep 27

Regulator Clarifies Insurers' Hong Kong Stock Connect ETF Investment Rules; Crealights' Southbound Stake Rises to 4.2%

Stock News
·
Sep 25

Hansoh Pharma's Application for Osteosarcoma Drug Accepted in China

MT Newswires Live
·
Sep 24

Hansoh Pharma’s BLA for B7-H3 ADC HS-20093 Accepted by China’s NMPA

Bulletin Express
·
Sep 24

Hansoh Pharma's HS-20093 Osteosarcoma Marketing Application Accepted by China's NMPA

Stock News
·
Sep 24

Hansoh Pharmaceutical - Biologics License Application of Risvutatug Rezetecan for Injection (Hs-20093) for Osteosarcoma Accepted by Nmpa

THOMSON REUTERS
·
Sep 24

BOCOM Intl Raises Hansoh Pharma Target Price to HK$46, Reiterates Buy Rating

Stock News
·
Sep 24

Movement Alert|HANSOH PHARMA Falls 3.09% in Regular Trading, Pharmaceuticals Sector Broadly Under Pressure

Market Focus
·
Sep 24

Hansoh Pharma Releases 2026 Interim Report and Promotes E-Communication Options for Registered Shareholders

Bulletin Express
·
Sep 23

Hansoh Pharma Publishes 2026 Interim Report; Shareholders Urged to Use Digital Access, Free Print Copies on Request

Bulletin Express
·
Sep 23

HANSOH PHARMA H1 2026 Profit Jumps 35.8% on Double-Digit Revenue Growth and Innovation Push

Bulletin Express
·
Sep 23

Hansoh Pharmaceutical Group Stock Falls 1.1% in Hong Kong

Dow Jones
·
Sep 23

Hansoh Pharma's Osteosarcoma Drug Included in Chinese Regulator's Priority Review

MT Newswires Live
·
Sep 22

Hansoh Pharmaceutical Says Risvutatug Rezetecan Included in NMPA Priority Review

Reuters
·
Sep 22